Lamivudine Sandoz (Lamivudine)

Lamivudine is a nucleoside analogue that is taken up by cells and phosphorylated to its active triphosphate form. This active metabolite competes with natural nucleotides for the active site of HIV reverse transcriptase and hepatitis B virus DNA polymerase, causing premature termination of the viral DNA chain and thereby blocking viral replication.

The dosage of lamivudine is individualized by the prescribing healthcare professional based on the specific indication, patient weight, renal function, and any concomitant antiretroviral regimen. Patients should follow the exact dosing instructions provided by their prescriber and not adjust the dose without medical guidance.

Safety data for lamivudine during pregnancy are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus. Breastfeeding decisions should be made in consultation with a healthcare provider, considering the drug’s excretion in milk.

To place an order, submit an enquiry on the Lamivudine Sandoz product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and is often combined with other antiretrovirals for a synergistic effect. Compared with some older NRTIs, lamivudine has a favorable safety profile, lower mitochondrial toxicity, and is active against both HIV and hepatitis B, making it a versatile component of many combination regimens.

Lamivudine tablets should be stored at ambient temperature, below 25 °C, in the original blister or container. Protect the product from moisture, direct sunlight, and excessive heat. Keep out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Lamivudine is administered orally, usually as a tablet taken with or without food. The exact frequency (once daily or twice daily) and dose are determined by the prescribing clinician based on the indication and patient-specific factors. Swallow the tablet whole with water; do not crush or chew unless specifically instructed.

Serious adverse events, although rare, include lactic acidosis, severe hepatotoxicity, and pancreatitis. Patients should be educated to seek immediate medical attention if they experience unexplained abdominal pain, rapid breathing, persistent nausea or vomiting, jaundice, or severe fatigue, as these may signal life‑threatening complications.

Lamivudine is contraindicated in patients with known hypersensitivity to lamivudine or any of the tablet excipients. Caution is also advised for individuals with severe renal impairment who have not had dose adjustments, and for those with pre‑existing mitochondrial disorders, as the drug may exacerbate underlying conditions.